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Abstract
LINE1 (L1) retrotransposons are genetic elements that are present in all mammalian genomes.
L1s are active in both humans and mice, and are capable of copying themselves and inserting the
copy into a new genomic location. These de novo insertions occasionally result in disease.
Endogenous L1 retrotransposons can be modified to increase their activity and mutagenic power
in a variety of ways. Here we outline the advantages of using modified L1 retrotransposons for
performing random mutagenesis in rodents and discuss several potential applications.
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Introduction
LINE1 (long interspersed nucleotide element 1 [L1]) elements
are important genome modifiers, altering mammalian
genomes in many ways. L1 elements have contributed to new
gene formation by inserting their own coding sequences into
genes, by shuffling other coding sequences through L1
mediated transduction, and by creating processed pseudo-
genes. They have created deletions both during their
retrotransposition (by their mechanism of integration) and
after insertion through unequal homologous recombination.
They have affected gene expression by altering both trans-
cription and translation of nearby genes. They have
expanded the genome by their continued retrotransposition
and by mediating retrotransposition of non-autonomous
retrotransposons (for reviews [1-6]). L1s have also been a
source of insertional mutagenesis, occasionally inserting
into genes and disrupting their function. In this review, we
discuss a practical application of L1 retrotransposons,
namely harnessing their mutagenic power by modifying
endogenous elements and using them to create mammalian
animal models.
A full-length active L1 retrotransposon is approximately
6,000 nucleotides long and encodes the proteins necessary
to mobilize itself to a new genomic location. The L1 retro-
transposon moves by a ‘copy and paste’ mechanism, which
means that the parent element remains in its original genetic
location, and a copy (de novo insertion) is inserted
somewhere else in the genome (as opposed to the ‘cut and
paste’ mechanism of DNA transposons, in which the parent
element is removed from its original genetic location and
inserted somewhere else). An L1 element is transcribed into
RNA and the bicistronic mRNA is exported from the nucleus
to the cytoplasm, where it is translated into open reading
frame (ORF)1 and ORF2 proteins. At least one L1 RNA
molecule, one ORF2 molecule, and one or more ORF1
molecules may assemble into a ribonucleoprotein (RNP)
complex. Then, both the ORF2 protein and associated L1
RNA must gain access to the nucleus, where the L1 RNA is
reverse transcribed and integrated into a new genomic
location by a process called target primed reverse
transcription (TPRT; Figure 1; for review [6]).
Advantages of using retrotransposons for
performing random mutagenesis
Genes can be disrupted completely and in a stable
manner
Retrotransposons can be used to deliver a gene trap that
efficiently splices into genes and disrupts their function. This
means that up to 30% of insertions (the percentage of the
genome that comprises gene exons and introns) may disrupta gene. This is a major improvement on chemical muta-
genesis, which creates point mutations that often do not
affect gene function. Also, unlike DNA transposon insertions,
L1 insertions are permanent and stable, eliminating the
possibility of losing the mutation over time.
Genes are randomly disrupted throughout the entire
genome
A complete genome-wide mutagenesis strategy requires
unbiased gene disruption. Although retrovirus-based muta-
genesis strategies result in ‘hotspots’ of mutation [7], L1
retrotransposons insert into the genome without apparent
site specificity. The L1 element contains an apurinic/
apyrimidinic endonuclease with an inexact target site
preference for 3’-AA/TTTT-5’ [8-10], which allows the L1
retrotransposon to insert randomly throughout the entire
genome. Recent human L1 insertions (within the past few
million years) have been found on every chromosome and
are present in introns, in intergenic regions, and in DNA
regions of high and low GC content [11]. The randomness of
de novo L1 insertions is well established by the study of
recent insertions from the various genome sequencing
projects, and we and others have confirmed random L1
insertion in mouse mutagenesis models [12,13]. Note that
the random pattern of de novo insertions is distinct from the
pattern that occurs after post-insertion selection bias has
taken place, which causes L1 elements to accumulate into
AT-rich and gene-poor regions. Post-insertion selection bias
occurs over millions of years and does not affect the
randomness of mutagenesis systems. Therefore, retro-
transposon based mutagenesis offers a significant advantage
over retrovirus based mutagenesis. It also offers an advan-
tage over insertional mutagenesis using DNA transposons
such as Sleeping Beauty (SB; a member of the Tc1/mariner
transposon family) [14] and piggyback (a DNA transposon
from the cabbage looper moth) [15], which insert non-
randomly when used for in vivo mutagenesis. The majority of
de novo transposon insertions occur within 3 megabases of
their original genomic location and 80% occur on the same
chromosome [16-19], a phenomenon termed ‘local hopping’.
Genes are disrupted at a high frequency
L1 retrotransposons have no limit on the number of
mutations that they can cause because they replicate by a
‘copy and paste’ mechanism. This is in contrast to DNA
transposons, which move by a ‘cut and paste’ mechanism and
are limited by the number of transposons in the transgenic
founder [20]. In an ideal germline mutagenesis strategy, each
germ cell would contain a single mutation that disrupts a
single gene that leads to a phenotype. Fewer mutations
introduce inefficiency, although more than one mutation per
germ cell is not necessarily ideal because matching mutations
to phenotypes becomes problematic. L1 retrotransposon
based mutagenesis has a high frequency of mutation,
approaching the ideal of one mutation per germ cell.
The genomic locations of mutations are easily mapped
L1 retrotransposons demonstrate cis preference, which
means that the retrotransposition proteins almost exclu-
sively mobilize the RNA that encoded them [21]. Therefore,
when inserting a tagged L1 retrotransposon into an animal,
one can be sure that all de novo insertions will be from
tagged L1 retrotransposons and not from retrotransposition
of other cellular mRNAs. Any new phenotypes will be due to
a tagged insertion that can be easily mapped, as opposed to
an untagged insertion that cannot be easily mapped. Unlike
N-ethyl-N-nitrosourea (ENU) base substitutions, de novo
retrotransposon insertions are large, unique sequences that
are relatively easy to map using inverse polymerase chain
reaction (PCR) or thermal asymmetric interlaced PCR.
Although easy mapping of mutations is a feature shared with
mutagenesis using transposons, the SB system has a
drawback. Recent experiments demonstrated that de novo
SB insertions occasionally occur via multiple sequential
‘hops’ from one chromosomal region to another [22,23], a
process that can result in large deletions. After SB excision
three terminal base pairs of the transposon remain, and
resolution of the double strand break occurs via the
nonhomologous end joining repair pathway, resulting in a
net 3 base pair insertion. Occasionally, through unknown
mechanisms, deletions occur at SB excision sites at lengths
of up to 100 base pairs [24,25]. Deletions created in this
manner are not associated with the transposon that caused
them because the transposon is excised during the event (cut
and paste mechanism), and so these mutations cannot easily
be mapped, which confounds attempts to link interesting
phenotypes with the causative mutation. L1s can cause
genomic deletions at insertion sites [26,27], but these
deletions remain associated with the L1 element that caused
them because the retrotransposon is not subsequently
excised (copy and paste mechanism) and so these mutations
can be identified more easily.
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Figure 1
Steps in L1 retrotransposition. L1, long interspersed nucleotide element 1
(LINE1); ORF, open reading frame; TPRT, target primed reverse
transcription.Animals that contain disrupted genes can be created
efficiently
Direct mutation in the germline produces offspring with
gene disruptions by natural breeding. This is important
because the use of embryonic stem cells can be costly, time
consuming, and technically impossible in most mammalian
models, including rat [28].
Table 1 provides a summary of the various methods of
mutagenesis in rodents. Many of the advantages of
mutagenesis using retrotransposons are shared with DNA
transposons, except as noted above, and their use is
discussed in other reviews in this supplement.
Mouse mutagenesis using L1 retrotransposons
Germline mutagenesis
The first description of an endogenous L1 causing a disease
in humans by insertional mutagenesis was reported in 1988.
In that instance, an L1 had inserted into the gene encoding
coagulation factor VIII, thereby causing hemophilia A [29].
Since that time, there have been more than 20 descriptions
of disease causing de novo L1 insertions in humans and mice
[2,6]. It is not apparent whether these endogenous L1 inser-
tions integrated directly into the germline during spermato-
genesis or oogenesis, or whether they integrated early
enough in development that they were later incorporated
into the germ cells, where they were passed on to future
generations. However, it is clear from the many instances of
insertional mutagenesis by endogenous L1s and by the
hundreds of thousands of L1 elements that have
accumulated in mammalian genomes that at least some de
novo insertions make their way into the germline and are
stably transmitted to offspring.
Proof-of-principle for germline mutagenesis in the mouse
using L1 retrotransposons was demonstrated in animals that
contained a transgene consisting of a highly active human L1
element tagged with a modified version of an enhanced
green fluorescent protein (EGFP) retrotransposition cassette
[30]. Several lines of transgenic mice were created. In some
lines the L1 element used its endogenous promoter for
transcription, and in others the L1 was driven by the
addition of a heterologous promoter. As expected, the endo-
genous L1 promoter was active in the germ cells. The
addition of the heterologous promoter increased transcript
levels in the germ cells and allowed for low levels of
transcription in multiple somatic tissues. Mouse lines that
contained either type of transgene demonstrated retro-
transposition, detected by reverse transcription PCR and
PCR of de novo insertions. Two germline insertions, one of
which had inserted into a gene intron, were cloned from
mice that had the heterologous promoter transgene. How-
ever, the transgenes in these initial mice did not contain
gene traps and were not expected to disrupt genes when
inserting into introns. The frequency of insertion was
estimated at approximately one de novo insertion in every
70 sperm for mice with the heterologous promoter, and
lower for mice containing the transgene that used only the
endogenous promoter. More refined estimates using real-
time PCR have demonstrated that some of these lines have
germline insertion frequencies as high as one insertion in
every 20 sperm.
Subsequent attempts at germline mutagenesis using L1
involved strategies to increase the frequency of retro-
transposition, including the use of a more active human L1
element, a different heterologous promoter, and a more
efficient retrotransposition cassette [13]. The highest repor-
ted frequency of germline transmission of de novo L1
insertions was estimated at one insertion in every three
sperm [12]. These transgenic mice contained a codon opti-
mized mouse L1 [31]. Although L1-based germline muta-
genesis will probably play a role in the creation of a genome-
wide collection of mouse knockouts, the existence of other
already well established methods for creating germline
mutations in mice (knockouts, knockins, and conditional
mutations, among others) may limit its usefulness.
Somatic mutagenesis
L1 elements are also capable of somatic mutagenesis.
However, little is known about the regulation, frequency,
and relevance of such retrotransposition. Two examples of
disease-causing somatic L1 insertions have been described in
humans, one associated with a case of colon cancer and the
other associated with a breast cancer. An L1 insertion into
exon 16 of the APC tumor suppressor, predicted to be an
inactivating mutation, was discovered in a human colon
cancer and was not present in adjacent normal tissue
[32,33]. An L1 insertion between exons 2 and 3 at the myc
locus was also identified in a ductal carcinoma of the breast,
although the functional implication of this mutation was not
determined [34]. These findings indicate that L1 elements
are occasionally active in somatic tissue and are capable of
driving carcinogenesis. However, the relative contribution to
oncogenic transformation is largely unknown. Growing
evidence that L1 elements become hypomethylated within
cancers suggest that L1 expression may be reactivated in
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Table 1
Comparison of gene knockout strategies in rodents
Criteria Retroviral ENU Retrotransposon
Disrupt genes completely Yes No Yes
Random mutation  No Yes Yes
High frequency mutation  Yes Yes Yes
Quickly map mutations  Yes No Yes
Efficiently create knockout animals No Yes Yes
ENU, N-ethyl-N-nitrosourea.somatic tissue and that retrotransposition may play a signi-
ficant role as an insertional mutagen, thereby contributing to
genomic instability [35-39]. Whether global L1 hypomethy-
lation augments L1 expression and retrotransposition
requires more rigorous investigation.
Human and synthetic mouse L1 sequences have proven to
retrotranspose in somatic tissue in transgenic mice
[12,13,40]. In one transgenic model, a highly active human
L1 element (L1RP) [41], which was tagged with an EGFP
retrotransposition cassette [42] and was transcribed using
its endogenous promoter, exhibited somatic retrotrans-
position within neuronal precursors [40]. However, it is not
known whether retrotransposition from endogenous L1
elements occurs in neuronal precursor cells in mice or
humans. In other transgenic mice, a native human L1
element (L1LRE3), tagged with a markerless retrotrans-
position cassette and driven by the mouse Hspa2 promoter,
demonstrated somatic retrotransposition into sites through-
out the genome, including transcriptional units, with 14.6%
of insertions found within RefSeq genes [13]. A synthetic,
codon optimized mouse L1 (ORFeus) tagged with an EGFP
retrotransposition cassette and driven by the CAG promoter
(a hybrid between the human cytomegalovirus immediate
early promoter and chicken β-actin promoter) was also
capable of a high level of somatic retrotransposition in
transgenic mice [12]. Because both high level ubiquitous
expression (with CAG) and codon optimization (ORFeus)
would both probably enhance retrotransposition, the
relative contributions of each of these factors in this trans-
genic mouse is unknown.
The most practical application of L1-based somatic muta-
genesis in mice would be a screen for tumor suppressors and
oncogenes. A tissue specific promoter could direct L1
mediated mutagenesis to a particular organ to drive the
formation of different types of cancers. The incidence of loss
of function mutations could be enhanced by tagging the L1
with a gene trap cassette containing strong splice acceptors.
For some trapped tumor suppressors a loss of heterozygosity
may be rate limiting for carcinogenesis, but could be
expedited by using a Blm mutant background. Germline
mutations in the RecQ-like helicase Blm causes a profound
increase in sister chromatid exchange, which is mediated by
homologous recombination, resulting in widespread cancer
[43].  Blm inactivation causes accelerated loss of hetero-
zygosity of the wild-type Apc allele in Apcmin/+ mice, causing
nearly four times as many polyps [43]. Because Blm appears
to repress cancer in multiple tissues, Blm mutants may be
useful for somatic mutagenesis in many different cell types.
Rat mutagenesis
Without question, the mouse is and will continue to be an
important animal model for performing functional
genomics. However, there are circumstances in which mouse
models are limited. The great majority of common human
diseases remain un-modeled in the mouse. Published knock-
outs exist for approximately 10% of mouse genes. Although
efforts are now underway to create publicly available
genome-wide collections of mouse knockouts, it will take
many years to achieve this goal, and it seems unlikely that
every gene in the mouse will be amenable to disruption
[44,45]. Furthermore, there are many instances in which
disrupting a gene in the mouse leads to no observable
phenotype. Rat models are an alternative to mice that may
enable the creation of new gene disruptions that are
unavailable in the mouse, and that can complement existing
transgenic mouse models. The evolutionary distance
between rats and mice, some 12 to 24 million years [46,47],
is about the same as that between humans and new world
monkeys [48]. Comparing mouse and rat models with
known human diseases can allow the distinction between
rodent specific phenotypes and those that may be general to
all mammals.
In many applications the rat is a better animal model for
human disease. Although mice have been the animal model
of choice for most geneticists, the rat has traditionally been
favored by physiologists and pathologists. Their larger size
make rats more conducive to study by instrumentation, and
facilitates manipulations such as blood sampling, studying
nerve conduction, or performing surgery. In many ways, rats
are physiologically more similar to humans than are mice.
For example, rats have a heart rate similar to that of
humans, whereas mice have a heart rate nearly ten times as
fast [28]. Rats have been used as important models for
human cardiovascular disease, diabetes, arthritis, and many
other autoimmune and behavioral disorders [28]. Rat
models are superior to mouse models for testing the
pharmacodynamics and toxicity of potential therapeutic
compounds, partially because the number and type of many
of their detoxifying enzymes are very similar to those in
humans [49].
Most techniques for genetic manipulation, including random
mutagenesis with a gene trap (both retrovirus-based and
non-retrovirus-based), gene knockouts, gene knockins, and
conditional mutations, depend upon embryonic stem (ES)
cells [50]. However, for unknown technical reasons, rat ES
cells cannot be isolated and used to create a viable organism
[51]. Consequently, many genetic manipulation techniques
widely used in the mouse have not been possible in the rat.
There are currently only two technologies that can be used to
produce rat models of human disease: cloning and chemical
mutagenesis using ENU. Although cloning could be used to
create rats with specific genetic modifications, by first
creating mutations in mitotic cells and then using the
mutated cells to clone a rat, this approach is extremely
inefficient. The first published attempt at cloning a rat had a
success rate of less than 1% [52]. Alternatively, ENU
mutagenesis is a common random mutagenesis gene knock-
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However, only a very small number of the total mutations
created by ENU mutagenesis have an observable phenotype
[53], and mapping mutations responsible for interesting
phenotypes is typically difficult and time consuming.
There is a need for new techniques that can rapidly create
and map gene knockouts in rats for the creation of new
models of human disease. Mutagenesis using transposable
elements is an attractive option. Indeed, a recent report
demonstrated the feasibility of using SB for mutagenesis in
rats [54]. We recently showed the feasibility of using L1 for
mutagenesis in the rat (Sprague-Dawley strain) and
demonstrated a high level of somatic retrotransposition with
occasional germline transmission of de novo insertions
(Kano H, Ostertag EM, Kazazian HH Jr, unpublished data).
Factors affecting the frequency and tissue
specificity of retrotransposition
When designing an L1 mutagenesis system, it is important to
consider the factors that will determine the frequency and
tissue specificity of retrotransposition. The following are
important considerations.
Choice of L1 element
At present, the human genome contains 80 to 100 endo-
genous full-length active L1s. Although they have similar
nucleic acid sequence, they are known to exhibit very
different levels of activity. A recent survey of the retro-
transposition capability of elements in the human genome
demonstrated there are just a few elements with very high
activity. These elements were called ‘hot’ L1s [55]. Another
study found that more active elements tend to insert larger
amounts of DNA during retrotransposition [56]. Therefore,
hot L1 elements such as L1RP and L1LRE3 are a good choice for
use in random mutagenesis because they are highly active
and better equipped to deliver gene traps. The L1RP element
was used in the initial studies of mouse models of L1
retrotransposition [30,57] and in a transgenic mouse model
that demonstrated somatic retrotransposition in neuronal
precursor cells [40]. A more recent study that demonstrated
L1 retrotransposition events at relatively high frequency and
characterized more than 50 de novo L1 insertions used the
L1LRE3 element [13].
Most mouse L1 elements cloned to date have exhibited poor
retrotransposition activity in a cultured cell assay when
compared with the hot human elements [58,59]. However,
the poor retrotransposition capability of mouse L1 elements
in cultured cells may be due to poor translation [60]. To
overcome this problem, Han and Boeke [31] designed a
synthetic mouse L1 that codon optimized the open reading
frames of an endogenous mouse L1 element without
changing the amino acid sequence. The codon optimized L1
(ORFeus) was used to create transgenic mice, in which it
demonstrated high activity [12]. In this model, all transgene
positive progeny demonstrated somatic insertions and some
insertions were passed through the germline.
Choice of retrotransposition cassette
The L1 element may be tagged with a retrotransposition
cassette to facilitate detection of de novo L1 insertions.
Retrotransposition cassettes are disrupted by an intron
sequence and are cloned into the 3’ untranslated region of an
L1 element. The intron is removed by splicing during a
retrotransposition event, allowing the differentiation
between a de novo L1 insertion and the L1 element(s)
present in the transgene. The cassette can contain a gene
that is disrupted by the intron and activated upon
retrotransposition, thereby allowing positive or negative
selection. For example, the EGFP cassette allows detection
of cells that contain a retrotransposition event by fluore-
scence [30,42]. A negative selection strategy could rescue
cells that would otherwise die by the expression of a rescue
gene upon retrotransposition. There are also cassettes that
contain no selectable marker. In these ‘markerless’ cassettes,
retrotransposition can be detected by PCR detection of loss
of the intron [13]. The main advantage of using a markerless
cassette is that it facilitates detection of smaller insertions.
The majority of L1 insertions are 5’ truncated during the
integration process. Therefore, a smaller cassette permits
detection of more insertions. Recent L1 transgenic mouse
studies demonstrated that more than 90% of de novo
insertions were 5’ truncated, and some of them were less
than 500 nucleotides [12,13].
Gene trapping technology can be used to maximize the rate
at which retrotransposition insertions interrupt coding
exons. Only about 1% of the genome is composed of exons.
Therefore, only one in every 100 random insertions is
expected to disrupt the coding sequence of a gene. A gene
trap that disrupts the normal splicing sequence of genes
during transcription can be included in the L1 retro-
transposon, such that retrotransposons that land within
gene introns in the correct orientation will disrupt gene
expression. Because approximately 30% of the mouse genome
consists of exons and introns [61], and new insertions are
likely to be in the correct orientation 50% of the time, this
strategy should increase the incidence of gene disruptions
resulting from retrotransposition events from 1% to
approximately 15%. To increase this rate of disruption even
further, we designed a unique bi-directional gene trap that
disrupts gene expression when inserted into an intron in
either orientation (and that can therefore be expected to
increase the rate of gene disruptions to approximately 30%
of all retrotransposition events) [13]. The gene trap that we
chose utilizes the very strong splice acceptor from the
human BCL2 gene, which is able to splice into exons located
more than 100 kilobases away without alternative splicing
[62]. This particular gene trap demonstrated 100% efficiency
(complete disruption of a gene with no alternative splicing)
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fully been used to disrupt genes in the mouse [64]. We have
demonstrated an L1 element tagged with the bi-directional
gene trap retrotransposition cassette can disrupt genes in
cultured cells and have used the cassette in transgenic
animals [13].
Choice of promoter
L1 elements contain an endogenous promoter [65], which is
sufficient to direct expression of the L1 transgene during
spermatogenesis and oogenesis in transgenic animals [30].
Transcripts produced by the endogenous promoter are
integrated either in the germline or early during
development, so the endogenous promoter can be used for
germline mutagenesis. The endogenous promoter has also
been used in transgenic mice that demonstrated retrotrans-
position in neuronal precursor cells [40]. Because L1
retrotransposition appears to be limited by the steady-state
levels of the processed L1 mRNA [66], a reasonable method
to increase retrotransposition frequency is by incorporating
a strong heterologous promoter. We and others have
demonstrated that a heterologous promoter can boost
retrotransposition for both germline [30] and somatic
mutagenesis [12,13].
A feasible somatic mutagenesis screen in mice would hinge
on robust and reliable expression in the desired tissues. This
can be achieved by removing the endogenous L1 promoter
and adding a strong tissue specific promoter. Unless the
promoter possesses a locus control region, expression of the
tagged L1 transgene may be affected significantly by the
genomic integration site. Ideally, L1 transgenes designed for
mutagenesis should have a promoter/enhancer that is
resistant to position effect silencing, such as the albumin,
α-fetoprotein, elastase, or β-globin promoters [67-72].
Alternatively, L1 transgenes can be targeted to specific loci in
mouse ES cells to recapitulate the tissue-specific expression
of that gene entirely. Recombinase mediated cassette
exchange is a useful method that is increasingly being used
to target particular loci, such as the β-actin locus [73].
Another alternative would be the incorporation of insulators
into the transgene, such as a chicken β-globin insulator [74-76].
Choice of genetic background
Mouse strain
From the large number of endogenous long terminal repeat
(LTR) retrotransposons that have inserted in mice, such as
intracisternal A particles (IAP) and early transposons (ETn),
it is known that mouse strain can affect the activity of LTR
retrotransposons [6,77]. Most IAP insertions have been
identified in C3H mice. ETn elements tend to retrotranspose
in A/J, SELH/Bc, and MRL/MpJ mice. It is unknown whether
genetic background is also important for L1 retrotrans-
position, because the number of endogenous L1 insertions
characterized in mice is much fewer than LTR retro-
transposon insertions. Characterized L1 insertions include
the spastic mouse in the SPE strain [78,79], the Orleans
reeler mouse in BALB/c [80], the black eyed white mouse in
C3H [81], the Chediak-Higashi mouse in C3H (with radiation
treatment) [82], the med mouse in PCT [83], and the retinal
degeneration mouse (strain not specified) [84]. All the L1
transgenic mice created to date were created in hybrid
strains, such as B6SJLF1 [12,13,30,57] and B6D2F1 [40].
Host factors
Little is known about the mechanisms by which the host
genome suppresses L1 retrotransposition, but several have
been reported as possibly involved. The L1 transgene on the
background of a mouse with retrotransposon defense
mechanisms knocked out or knocked down could potentially
produce more insertions.
DNA methylation has been proposed to be a major defense
mechanism against transposable elements, not only
inhibiting transcription but also assembling sequences into
the condensed state to prevent recombination [85]. Both
human and mouse L1s contain CpG islands in the 5’
untranslated region, which contains the L1 promoter activity
[65,86]. It is believed that the CpG island of L1 is maintained
in heavily methylated status most of the time. It is
noteworthy that the human L1 promoter is heavily methy-
lated even in the mouse genome, and the retrotransposition
activity of human L1 transgene seems to be correlated with
its methylation status (Kano H, Ostertag EM, Kazazian HH
Jr, unpublished data). The L1 transgene flanked by an
insulator sequence retains unmethylated CpGs in its 5’
untranslated region and shows higher retrotransposition
activity than that of methylated L1 transgene without the
insulator sequence (Kano H, Ostertag EM, Kazazian HH Jr,
unpublished data).
DNA methyltransferase 3L (encoded by Dmnt3L) is required
for the de novo methylation of retrotransposons. Dnmt3L is
expressed in testis, and Dnmt3L knockout in mice causes
high levels of transcription of retrotransposons in spermato-
gonia and spermatocytes [87]. Male mice that are homo-
zygous for the Dnmt3L knockout allele are unable to
produce sperm. Therefore, mutagenesis in Dnmt3L deletion
males would need to be performed by using conditional
mutations of Dnmt3L  or by using a retrotransposition
cassette that expresses a copy of Dnmt3L upon retro-
transposition, which might restore spermatogenesis only in
those spermatogonia that contain a de novo insertion.
Lymphoid-specific helicase (Lsh) is a member of the SNF2
family of chromatin remodeling proteins. Contrary to the
retrotransposon reactivation in male germ cells of Dnmt3L
knockout,  Lsh knockout mice exhibit demethylation and
transcriptional reactivation of repetitive elements in the
female germline. Lsh is essential in epigenetic silencing of
retrotransposons in the female meiosis [88,89]. Lsh deletion
mice exhibit severe oocyte loss and lack of ovarian follicle
formation, making mutagenesis on this background difficult.
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(APOBEC) family consists of APOBEC1, APOBEC2, and
APOBEC3A, B, C, D/E, F, G, and H. Among them, APOBEC3G
is the best characterized and is known to catalyze C to U
deamination of the minus strand during reverse trans-
cription. Thus, APOBEC3G produces inactivated copies of
LTR retrotransposons, but not L1, by introducing mutations.
APOBEC3A, B, C, and F have been reported to inhibit L1
retrotransposition in the cultured cells [90-92]. However,
the precise mechanism of L1 suppression by these APOBECs
is not well understood, because they do not increase the
number of mutations in retrotransposed copies of L1. Mice
and rats have the APOBEC1 and APOBEC2 genes and only a
single  APOBEC3 gene. The mouse APOBEC3 may not be
involved in repression of retrotransposons because the
APOBEC3 knockout mouse unexpectedly demonstrated
normal development, survival, and fertility. In addition,
wild-type mice exhibit poor expression of APOBEC3 in testis
[93]. Therefore, it is unclear at this point whether the
APOBEC genes affect L1 retrotransposition in vivo or
whether the APOBEC knockout mice could be used to boost
retrotransposition from an L1-containing transgene.
Conclusion
Endogenous L1 elements have caused both germline
transmissible and somatic insertions in humans and mice.
We and other groups have demonstrated that modified L1
elements can be used to perform random mutagenesis in
mice or rats. Depending on the promoter used to drive
transcription, either germline or somatic mutagenesis is
feasible. Given the urgent need for rat models of human
diseases and the limited methods for performing
mutagenesis in rats, L1 based mutagenesis is an attractive
option. When designing an L1 transgene for mutagenesis, it
is important to consider the activity of the retrotransposon,
the type of retrotransposition cassette used to detect
insertions, the strength and tissue specificity of the promoter
used to drive transcription of the L1, and the genetic
background of the animal model.
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